Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Palonosetran: Phase III

MOGN and Helsinn presented data from study 99-03, an international Phase III double-blind trial in 563 patients receiving high or low-dose palonosetron 5-HT3 serotonin receptor antagonist

Read the full 261 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE